Atossa Therapeutics, Inc. (NASDAQ: ATOS) rose eight cents, or 4.1%, to $2.04 in early Wednesday trading. Atossa recently filed for shelf of up to 13 million shares of common stock by selling stockholders.
Atossa hasn’t sat around waiting for those shares to change hands; it’s been active in its field of late.
The Seattle-based Atossa, a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, announced earlier this month that an ovarian cancer patient has begun treatment with Atossa’s proprietary oral Endoxifen.
The U.S. Food and Drug Administration previously issued a “Safe to Proceed” letter under their expanded access pathway, permitting the use of Atossa’s oral Endoxifen in this patient.
The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief.
“The patient has recurrent ovarian cancer and did not tolerate tamoxifen, which is sometimes prescribed for ovarian cancer as well as breast cancer,” commented CEO Steven Quay.
“The patient recently underwent functional molecular genomic testing using 3D tumor organoid cultures grown in the laboratory from the patient’s tumor to help determine potential therapies. This testing revealed that the combination of Endoxifen and alpelisib produced an exceptional tumor response. We will follow the progress of this patient and consider additional clinical studies in patients with ovarian cancer.”
Under the FDA expanded access program, the use of Atossa’s proprietary oral Endoxifen is restricted solely to this patient.